English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

We investigated the association between the current use of individual sulphonylureas and the risk of a first‐ever acute myocardial infarction (AMI) and all‐cause mortality, in a population‐based cohort study, using primary care data from the Clinical Practice Research Datalink database (2004‐2012). New users ( N  = 121 869), aged ≥18 years, with at least one prescription for a non‐insulin antidiabetic agent were included. The first prescription defined start of follow‐up. Time‐dependent Cox proportional hazard models were used to estimate the risk of a first‐ever AMI and all‐cause mortality associated with the use of individual sulphonylureas, and other non‐insulin glucose‐lowering drugs. No differences in risk of a first‐ever AMI (adjusted hazard ratio [HR] 1.02, 95% confidence interval [CI] 0.70‐1.50) or all‐cause mortality (adjusted HR 0.97, 95% CI 0.80‐1.17) were observed when comparing gliclazide use with non‐gliclazide sulphonylurea use. Similar results were found for each individual sulphonylurea. As evidence is accumulating that gliclazide is no safer than other sulphonylureas, current guidelines suggesting superiority should be carefully evaluated.

Risk of a first‐ever acute myocardial infarction and all‐cause mortality with sulphonylurea treatment: A population‐based cohort study